Detailed Narrative
Strong Financial Performance and Margin Expansion
Shilpa Medicare reported its highest-ever quarterly EBITDA of ₹110 crores in Q2 FY26, a 21% increase year-on-year, crossing the ₹100 crore mark for the first time. Revenues for the quarter stood at ₹372 crores, growing 7% YoY, while H1 FY26 revenues reached ₹700 crores, up 8%. Gross margin improved to 72% in Q2 and 74% in H1, driven by a stronger product mix. The EBITDA margin for both Q2 and H1 was 30%, reflecting a 4% and 3% improvement YoY, respectively. PAT for the quarter was ₹44 crores, with H1 PAT at ₹91 crores, surpassing the full-year PAT of FY25 (₹78 crores).
Strategic Focus on Complex and Differentiated Products
The company emphasized its strategy of operating in advanced, complex, and high-entry barrier segments like API, Formulations, and Biologics. This approach is reflected in the improved adjusted ROCE (excluding Biologics and NBE investments), which rose from 4% in FY23 to approximately 17% in H1 FY26. Management highlighted a focus on better asset utilization and monetizing existing investments in Biologics, transdermal facilities, and fermentation facilities over the next 3-5 years, leveraging its technical know-how and R&D capabilities.
Key Product Launches and Pipeline Progress
Shilpa Medicare successfully launched its first NCE program, NorUrsodeoxycholic acid, in India, being the only company globally to bring this product to market. Commercial supplies for another NCE program are expected from Q4 FY26, with a second NCE program filing anticipated in FY27. In the non-oncology segment, Tranexamic Acid is expected to reach full capacity utilization this year, with an additional 100 metric tons capacity planned for next financial year. Commercial supplies for Ursodeoxycholic Acid and NorUrsodeoxycholic Acid (API) are slated to begin in Q3 FY26.
Advancements in CDMO and Biologics
The CDMO business shows good traction, with several programs advancing. The dedicated facility for Lanthanum Dioxycarbonate is set for commissioning in Q3 FY26, with commercial launch expected next financial year. On the peptide front, Semaglutide's PV batches are initiated, and a large dedicated peptide facility is planned for commissioning next financial year. In Biologics, two new NBE programs are expected to enter Phase I human studies in FY27, and the first ADC biosimilar is also planned for human studies in FY27. Aflibercept, the most advanced biosimilar program, is targeted for launch in FY27 after successful Phase III studies.
European Market Expansion and US Submissions
In the European market, Nilotinib continues to gain market share, with limited generic competition expected. Approval for the complex Rotigotine transdermal patch is anticipated in Q4 FY26. For the US market, clinical studies for a transdermal patch have been completed, with submission planned for Q3 FY26, and filing for two other patches expected next financial year. The company is also planning to file for Ondansetron long-acting injection in India in Q4 FY26, with a launch targeted for next financial year, addressing a unique market need for advanced antiemetic patients.
Capital Expenditure and Debt Management
The company incurred capex investments of ₹153 crores in H1 FY26. For the remainder of FY26, an additional capex of ₹75-100 crores is planned, primarily for the Albumin facility and API business expansion. Net debt at the end of September stood at ₹569 crores. Management stated that interest outgo has stabilized, and future capex programs are expected to be funded through internal accruals, indicating a focus on financial prudence and self-sufficiency.